DE69638145D1
(de)
*
|
1995-04-14 |
2010-04-22 |
Us Gov Health & Human Serv |
Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
|
US7517527B2
(en)
|
1995-10-30 |
2009-04-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin with in vivo T cell suppressant activity and methods of use
|
US6632928B1
(en)
|
1997-03-05 |
2003-10-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxins and methods of inducing immune tolerance
|
US7288254B2
(en)
|
1995-10-30 |
2007-10-30 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih |
Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
|
US7696338B2
(en)
|
1995-10-30 |
2010-04-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin fusion proteins and means for expression thereof
|
US7125553B1
(en)
|
1996-04-15 |
2006-10-24 |
The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention |
Methods of inducing immune tolerance using immunotoxins
|
AU736501B2
(en)
*
|
1997-03-05 |
2001-07-26 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Novel vectors and expression methods for producing mutant proteins
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
CN1086945C
(zh)
*
|
1997-06-03 |
2002-07-03 |
胡章英 |
白喉口服液
|
GB9923060D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Chiron Spa |
Vaccine
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
GB0211118D0
(en)
*
|
2002-05-15 |
2002-06-26 |
Polonelli Luciano |
Vaccines
|
WO2004011027A1
(fr)
*
|
2002-07-30 |
2004-02-05 |
Baxter International Inc. |
Vaccins multivalents chimeres a conjugue polysaccharidique
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
MY144231A
(en)
|
2003-12-17 |
2011-08-15 |
Wyeth Corp |
Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
|
EA012984B1
(ru)
|
2003-12-17 |
2010-02-26 |
Вайет |
Конъюгаты иммуногенных пептидных носителей и способы их получения
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
IL308456A
(en)
|
2005-04-08 |
2024-01-01 |
Wyeth Llc |
A multivalent pneumomuroral protein-polysaccharide conjugate preparation
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
CA2654014A1
(fr)
*
|
2006-05-31 |
2007-12-06 |
Silvio Buzzi |
Utilisation pharmaceutique de molecules proteiques immunologiquement correlees a la toxine diphterique
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
CN101265288B
(zh)
*
|
2007-03-13 |
2012-03-21 |
齐鲁制药有限公司 |
Crm197突变体的纯化方法
|
WO2010125480A1
(fr)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Vaccin anti-pneumococcique et ses utilisations
|
NZ597191A
(en)
|
2009-06-22 |
2013-11-29 |
Wyeth Llc |
Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
|
BRPI1015567A2
(pt)
|
2009-06-22 |
2021-08-31 |
Wyeth Llc |
Composições imunogênicas de antígenos de staphylococcus aureus
|
IT1398927B1
(it)
|
2009-06-25 |
2013-03-28 |
Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi |
Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
|
AU2010201410B2
(en)
*
|
2010-03-30 |
2015-04-30 |
Pelican Technology Holdings, Inc. |
High level expression of recombinant CRM197
|
MX343356B
(es)
|
2010-03-30 |
2016-11-03 |
Pfenex Inc * |
Toxinas proteicas recombinantes de alto nivel de expresion.
|
EP2575870B1
(fr)
|
2010-06-04 |
2016-12-07 |
Wyeth LLC |
Formulations vaccinales
|
WO2011154878A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Vaccin peptidique ige ch3
|
EP3246044B2
(fr)
|
2010-08-23 |
2024-04-10 |
Wyeth LLC |
Formulations stables des antigènes rlp2086 de neisseria meningitidis
|
ES2864635T3
(es)
|
2010-09-10 |
2021-10-14 |
Wyeth Llc |
Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
|
EP2716661B1
(fr)
|
2011-06-01 |
2018-03-07 |
Xiamen University |
Protéine de fusion comprenant le mutant non toxique de la toxine diphtérique crm197 ou un fragment de celui-ci
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
MY167723A
(en)
|
2012-03-09 |
2018-09-21 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
US9169304B2
(en)
|
2012-05-01 |
2015-10-27 |
Pfenex Inc. |
Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
US9777076B2
(en)
|
2012-07-16 |
2017-10-03 |
Pfizer Inc. |
Saccharides and uses thereof
|
CN102766647A
(zh)
*
|
2012-07-25 |
2012-11-07 |
天津康希诺生物技术有限公司 |
在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
|
MX363511B
(es)
|
2012-08-16 |
2019-03-26 |
Pfizer |
Proceso de glucoconjugación y composiciones.
|
ES2848048T3
(es)
|
2012-10-03 |
2021-08-05 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas
|
KR20140075201A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP4169929A1
(fr)
|
2012-12-20 |
2023-04-26 |
Pfizer Inc. |
Compositions immunogènes comprenant le pn- serotype 12f
|
JP6359561B2
(ja)
|
2013-01-04 |
2018-07-18 |
オービーアイ ファーマ インコーポレイテッド |
高い炭水化物抗原密度を有するワクチン及び新規サポニンアジュバント
|
ES2685894T3
(es)
|
2013-03-08 |
2018-10-15 |
Pfizer Inc. |
Polipéptidos de fusión inmunogénicos
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
CN104140972B
(zh)
*
|
2013-05-07 |
2018-01-23 |
上海惠盾生物技术有限公司 |
白喉毒素突变体crm197的制备方法
|
WO2015031151A1
(fr)
|
2013-08-26 |
2015-03-05 |
Corning Incorporated |
Procédé de recuisson localisée d'un verre renforcé chimiquement
|
WO2015033251A2
(fr)
|
2013-09-08 |
2015-03-12 |
Pfizer Inc. |
Compositions utilisables contre neisseria meningitidis et procédés associés
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
IL296681B2
(en)
|
2014-01-21 |
2024-09-01 |
Pfizer |
Immunogenic preparations including conjugated capsular saccharide antigens and their uses
|
EP3957321A3
(fr)
|
2014-01-21 |
2022-07-13 |
Pfizer Inc. |
Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci
|
HUE055553T2
(hu)
|
2014-01-21 |
2021-12-28 |
Pfizer |
Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CA2938251C
(fr)
|
2014-01-31 |
2021-01-12 |
Fina Biosolutions, Llc |
Expression et purification de crm197 et de proteines associees
|
CA2939416A1
(fr)
|
2014-02-14 |
2015-08-20 |
Pfizer Inc. |
Conjugues de glycoproteine immunogenes
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
US10280409B2
(en)
|
2014-11-20 |
2019-05-07 |
Biological E Limited |
Codon optimized polynucleotide for high level expression of CRM197
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
KR20190049940A
(ko)
|
2015-02-19 |
2019-05-09 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
PE20180172A1
(es)
|
2015-05-04 |
2018-01-22 |
Pfizer |
Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
|
US11147863B2
(en)
|
2015-06-23 |
2021-10-19 |
Biological E Limited |
Multivalent pneumococcal conjugate vaccine
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
WO2017085586A1
(fr)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
|
US11965009B2
(en)
|
2016-03-10 |
2024-04-23 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
CN109790545A
(zh)
|
2016-03-10 |
2019-05-21 |
约翰·霍普金斯大学 |
产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途
|
WO2017220753A1
(fr)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugué polysaccharide pneumococcique-protéine
|
EP3269385A1
(fr)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugués de polysaccharide-protéine pneumococcique
|
JP7001687B2
(ja)
|
2016-08-05 |
2022-02-04 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物
|
JP7001686B2
(ja)
|
2016-08-05 |
2022-02-04 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体-タンパク質コンジュゲート組成物
|
CU24660B1
(es)
|
2016-09-30 |
2023-05-11 |
Biological E Ltd |
Composiciones de vacunas multivalentes que comprenden conjugados de polisacárido-proteína de streptococcus pneumoniae utilizando proteínas portadoras psaa y crm197
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
US11951165B2
(en)
|
2016-12-30 |
2024-04-09 |
Vaxcyte, Inc. |
Conjugated vaccine carrier proteins
|
KR20190103256A
(ko)
|
2016-12-30 |
2019-09-04 |
수트로박스, 인코포레이티드 |
비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
|
PL3570879T3
(pl)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
KR101908590B1
(ko)
|
2017-02-01 |
2018-10-16 |
(주)포바이오코리아 |
Crm197의 용해성 단백질 발현 및 정제 방법
|
US11246918B2
(en)
|
2017-02-03 |
2022-02-15 |
Eva Barbara Schadeck |
Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
ES2926535T3
(es)
*
|
2017-04-22 |
2022-10-26 |
Biological E Ltd |
Método mejorado para la producción de alto nivel de CRM
|
FI3678654T3
(fi)
|
2017-09-07 |
2024-09-02 |
Merck Sharp & Dohme Llc |
Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa
|
CN117982633A
(zh)
|
2017-12-06 |
2024-05-07 |
默沙东有限责任公司 |
包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
|
KR102475419B1
(ko)
*
|
2018-07-16 |
2022-12-07 |
주식회사 유바이오로직스 |
Crm197을 고농도로 발현하는 코리네박테리움 균주
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
BR112021005425A2
(pt)
|
2018-09-23 |
2021-06-15 |
Biological E Limited |
polissacarídeos capsulares purificados de streptococcus pneumoniae
|
CN109100517A
(zh)
*
|
2018-10-08 |
2018-12-28 |
武汉生命科技股份有限公司 |
一种用于检测白喉抗体的抗原蛋白、试剂盒及制备方法
|
CA3120922A1
(fr)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations
|
SG11202106541WA
(en)
|
2018-12-19 |
2021-07-29 |
Merck Sharp & Dohme |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(fr)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations
|
EP4003410A1
(fr)
|
2019-07-31 |
2022-06-01 |
Sanofi Pasteur, Inc. |
Compositions de conjugués de polysaccharide-protéine pneumococcique multivalents leurs méthodes d'utilisation
|
WO2021084429A1
(fr)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Compositions d'escherichia coli et méthodes associées
|
BR112022015796A2
(pt)
|
2020-02-21 |
2022-10-11 |
Pfizer |
Purificação de sacarídeos
|
WO2021165928A2
(fr)
|
2020-02-23 |
2021-08-26 |
Pfizer Inc. |
Compositions d'escherichia coli et méthodes associées
|
EP3900739A1
(fr)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
|
EP3919076A1
(fr)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
|
EP4203995A1
(fr)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations
|
MX2023003169A
(es)
|
2020-09-17 |
2023-03-27 |
Janssen Pharmaceuticals Inc |
Composiciones de vacunas multivalentes y usos de las mismas.
|
EP4232593A1
(fr)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Procédés de purification de polysaccharides bactériens
|
AU2021368151B2
(en)
|
2020-10-27 |
2024-09-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
KR20220102871A
(ko)
|
2021-01-14 |
2022-07-21 |
(주)셀트리온 |
다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
WO2022234416A1
(fr)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination contre des infections à pneumocoque et à covid-19
|
EP4333879A1
(fr)
|
2021-05-03 |
2024-03-13 |
Pfizer Inc. |
Vaccination contre des infections bactériennes et à betacoronavirus
|
EP4346892A2
(fr)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
WO2022249107A2
(fr)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
IL314243A
(en)
|
2022-01-13 |
2024-09-01 |
Pfizer |
Immunogenic preparations containing conjugates of capsular sugar antigen and their uses
|
WO2023161817A1
(fr)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
|
WO2023218322A1
(fr)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Procédé de production de formulations de vaccin avec des conservateurs
|
WO2024084397A1
(fr)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination contre infections à pneumocoques et à covid-19
|
WO2024089001A1
(fr)
|
2022-10-24 |
2024-05-02 |
Idorsia Pharmaceuticals Ltd |
Vaccin contre klebsiella pneumoniae
|
WO2024110827A1
(fr)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(fr)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Formulations de vaccin pneumococcique conjugué
|
WO2024121280A1
(fr)
|
2022-12-08 |
2024-06-13 |
Idorsia Pharmaceuticals Ltd |
Vaccin contre klebsiella pneumoniae
|
WO2024166008A1
(fr)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|